Eupraxia Pharmaceuticals (NASDAQ:EPRX) Given Buy Rating at HC Wainwright

Eupraxia Pharmaceuticals (NASDAQ:EPRX)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They presently have a $12.00 price objective on the stock. HC Wainwright’s target price suggests a potential upside of 39.70% from the company’s previous close.

Several other equities analysts have also issued reports on EPRX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Wednesday, October 8th. Leede Financial raised Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, October 29th. Lifesci Capital raised Eupraxia Pharmaceuticals to a “strong-buy” rating in a report on Thursday, December 11th. Finally, Wall Street Zen upgraded Eupraxia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Eupraxia Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $11.67.

Eupraxia Pharmaceuticals Trading Up 19.1%

EPRX opened at $8.59 on Friday. The company has a market cap of $308.90 million, a price-to-earnings ratio of -9.87 and a beta of 1.21. The stock has a fifty day simple moving average of $6.53 and a two-hundred day simple moving average of $5.85. Eupraxia Pharmaceuticals has a 12-month low of $2.68 and a 12-month high of $8.70.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last released its earnings results on Tuesday, November 4th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.04. On average, analysts predict that Eupraxia Pharmaceuticals will post -0.67 EPS for the current year.

Institutional Trading of Eupraxia Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Bank of America Corp DE raised its stake in shares of Eupraxia Pharmaceuticals by 402.4% in the second quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock worth $72,000 after purchasing an additional 10,059 shares during the last quarter. Quadrature Capital Ltd bought a new stake in Eupraxia Pharmaceuticals in the 2nd quarter worth about $61,000. TCI Wealth Advisors Inc. purchased a new position in Eupraxia Pharmaceuticals in the 3rd quarter worth about $65,000. Integrated Wealth Concepts LLC purchased a new position in Eupraxia Pharmaceuticals in the 3rd quarter worth about $71,000. Finally, JPMorgan Chase & Co. lifted its stake in Eupraxia Pharmaceuticals by 593.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company’s stock valued at $108,000 after acquiring an additional 16,017 shares during the period.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.